Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the ...

BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

Investing.com - Investors should expect some moderation in growth in the S&P 500 in 2025 after two years of over 20% expansion in the benchmark index, according to ...

In recent trading, shares of Verona Pharma plc (Adderbury) (Symbol: VRNA) have crossed above the average analyst 12-month target price of $47.28, changing hands for $48.20/share. When a stock ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

Highlights:,Debt acts as a means for companies to access capital, but it introduces risks if not managed ...

Sanofi S.A. Part Cert 0.06% €8.19M ...